Personalis, Inc., National Cancer Center, and Ono Pharmaceutical Co., Ltd. announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency (dMMR). As part of the collaboration on the VOLTAGE-2 study, an exploratory analysis will be conducted to evaluate specific biomarkers such as minimal residual disease (MRD) status that may have prognostic or predictive value for patient care.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.265 USD | +1.20% | -1.94% | -39.76% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,300 JPY | +1.34% | +2.77% | 6.86B | ||
1.265 USD | +1.20% | -1.94% | 64.78M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.76% | 64.78M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PSNL Stock
- News Personalis, Inc.
- Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer